NCT06885424
A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2 Bio) Gene Therapy (GT) Products
Enrolling by Invitation
Not specifiedAges 18+ObservationalA2 Biotherapeutics Inc.
~400 participants
Updated 2026-05-20 on ClinicalTrials.gov
What's tested:No additional intervention administered in this long term follow-up study
At a glance
Recruiting sites
0 of 3 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Long-term safety of previous A2 Bio GT treatment
Measured over 15 years post treatment with A2 Bio GT product
Conditions
NCT06885424
Where you'd take part
This study runs at 3 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Banner Health
Gilbert, Arizonano site contact published
Mayo Clinic
Rochester, Minnesotano site contact published
NYU Langone Medical Center
New York, New Yorkno site contact published
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Eric Ng, MD · STUDY_DIRECTOR · A2 Biotherapeutics
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Long-term safety of previous A2 Bio GT treatment15 years post treatment with A2 Bio GT product
Long-term safety of previous A2 Bio GT treatment as determined by incidence of adverse events (AEs)